Halopemide

Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].

Product Specifications

CAS Number

[59831-65-1]

UNSPSC

12352005

Hazard Statement

H302

Target

Dopamine Receptor; Phospholipase

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/halopemide.html

Purity

99.65

Solubility

DMSO : 41.67 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(C=C1)F)NCCN2CCC(CC2)N3C4=CC=C(C=C4NC3=O)Cl

Molecular Formula

C21H22ClFN4O2

Molecular Weight

416.88

Precautions

H302

References & Citations

[1]Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5 (2) :108-17.|[2]Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl) . 1981;75 (3) :254-7.|[3]Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234 (4) :4825-4839.